Flamingo Therapeutics Shares Insights on Immune Modulation at AACR

Flamingo Therapeutics Shares Insights on Immune Modulation at AACR

Flamingo Therapeutics is excited to reveal that an abstract concerning their notable research on danvatirsen has been accepted for presentation at a prestigious annual meeting of the American Association for Cancer Research (AACR). This event occurs while at the forefront of cancer research, bringing together thought leaders and innovators dedicated to advancing the fight against cancer. The presentation highlights the immune-modulatory effects of danvatirsen, an agent designed to enhance the effectiveness of immunotherapies.

Details of the Presentation

The poster presentation at the AACR will feature the following highlights:

Poster Title: "ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies"

Session Category/Title: Immunology/Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression

Session Time: April 28, 2025, from 9:00 AM to 12:00 PM

Location: Poster Section 38

Published Abstract Number: 2244

About Flamingo Therapeutics

Flamingo Therapeutics is at the forefront of revolutionizing cancer treatment through innovative RNA-targeted therapies. They focus on effectively addressing complex challenges in oncology, particularly those involving difficult-to-target transcription factors and long non-coding RNAs. The company has formed a strategic partnership with Ionis Pharmaceuticals to enhance the development of their clinical pipeline.

Flamingo also enjoys support from notable biotechnology investors, which includes Abrdn, Andera Partners, and Bpifrance, among others. This funding is crucial as it enables Flamingo to pursue groundbreaking research and clinical studies that could significantly impact cancer care.

Current Clinical Trials Involving Danvatirsen

Flamingo has initiated a Phase II clinical trial known as 'PEMDA-HN'. This study evaluates the effects of danvatirsen, focused on targeting the STAT3 protein in combination with pembrolizumab for patients suffering from head and neck squamous cell carcinoma (HNSCC). The trial aims to determine how effectively this combination can enhance treatment outcomes for this challenging cancer.

Additionally, a Phase I investigator-initiated trial is underway that assesses danvatirsen as a monotherapy and in conjunction with venetoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These trials underscore Flamingo's commitment to advancing available treatment options in oncology.

Engage With Flamingo Therapeutics

Flamingo Therapeutics encourages individuals interested in their work and developments in the field of cancer research to engage with them on social media platforms. They are active on LinkedIn, providing regular updates regarding their research initiatives, clinical trials, and corporate developments. As a company dedicated to transparency and collaboration, Flamingo welcomes community engagement.

Frequently Asked Questions

What is the focus of Flamingo Therapeutics?

Flamingo Therapeutics specializes in RNA-targeted therapies for innovative cancer treatments.

What is the significance of the AACR annual meeting?

The AACR annual meeting is a major event where researchers present their latest findings in cancer research, contributing to the scientific conversation around oncology.

How does danvatirsen work?

Danvatirsen targets the STAT3 protein, aiming to reduce immunosuppression within tumors and make them more receptive to immunotherapies.

What types of cancer are being targeted in Flamingo's trials?

Flamingo Therapeutics focuses on head and neck squamous cell carcinoma and acute myeloid leukemia, among other cancers.

How can I learn more about Flamingo Therapeutics?

To discover more about Flamingo Therapeutics, visit their official website or follow their updates on LinkedIn.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.